Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S)

被引：0
|
作者：
Jonasch, Eric
Hasanov, Elshad
Motzer, Robert J.
Hariharan, Subramanian
Choueiri, Toni K.
Huang, Bo
Haanen, John B. A. G.
Albiges, Laurence
Venugopal, Balaji
Schmidinger, Manuela
Larkin, James M. G.
Grimm, Marc-Oliver
Negrier, Sylvie
Wang, Jing
Mariani, Mariangela
Chudnovsky, Aleksander
di Pietro, Alessandra
Rini, Brian I.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Pfizer Inc, New York, NY USA
[4] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Boston, MA USA
[6] Pfizer Inc, Groton, CT 06340 USA
[7] Netherlands Canc Inst, Amsterdam, Netherlands
[8] Inst Gustave Roussy, Villejuif, France
[9] Univ Glasgow, Glasgow, Lanark, Scotland
[10] Med Univ Vienna, Vienna, Austria
[11] Royal Marsden NHS Fdn Trust, London, England
[12] Jena Univ Hosp, Jena, Germany
[13] Univ Lyon, Ctr Leon Berard, Lyon, France
[14] Pfizer Inc, Cambridge, MA USA
[15] Pfizer SRL, Milan, Italy
[16] Cleveland Clin, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
687
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Association of C-reactive protein (CRP) with efficacy of avelumab plus axitinib (A plus Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.
    Tomita, Yoshihiko
    Larkin, James
    Venugopal, Balaji
    Haanen, John B. A. G.
    Kanayama, Hiro-Omi
    Eto, Masatoshi
    Grimm, Marc-Oliver
    Fujii, Yosuke
    Umeyama, Yoshiko
    Mariani, Mariangela
    Di Pietro, Alessandra
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101
    Tomita, Y.
    Motzer, R. J.
    Choueiri, T. K.
    Rini, B., I
    Miyake, H.
    Uemura, H.
    Albiges, L.
    Fujii, Y.
    Umeyama, Y.
    Wang, J.
    Mariani, M.
    Schmidinger, M.
    ESMO OPEN, 2022, 7 (02)
  • [23] Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial
    Grimm, Marc-Oliver
    Oya, Mototsugu
    Choueiri, Toni K.
    Motzer, Robert J.
    Schmidinger, Manuela
    Quinn, David I.
    Gravis-Mescam, Gwenaelle
    Verzoni, Elena
    Van den Eertwegh, Alfonsus J. M.
    di Pietro, Alessandra
    Mariani, Mariangela
    Wang, Jing
    Thomaidou, Despina
    Albiges, Laurence
    EUROPEAN UROLOGY, 2024, 85 (01) : 8 - 12
  • [24] Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
    Tomita, Y.
    Motzer, R. J.
    Choueiri, T. K.
    Rini, B. I.
    Miyake, H.
    Oya, M.
    Albiges, L.
    Aizawa, M.
    Umeyama, Y.
    Wang, J.
    di Pietro, A.
    Schmidinger, M.
    ESMO OPEN, 2023, 8 (06)
  • [25] Randomized phase III trial of avelumab plus axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis
    Uemura, M.
    Tomita, Y.
    Miyake, H.
    Hatakeyama, S.
    Kanayama, H-O.
    Numakura, K.
    Takagi, T.
    Kato, T.
    Eto, M.
    Obara, W.
    Uemura, H.
    Motzer, R. J.
    Fujii, Y.
    Kamei, Y.
    Oya, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
    Zhang, Yue
    Wu, Shenhong
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S585 - S588
  • [27] Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.
    Froehner, Michael
    EUROPEAN UROLOGY, 2024, 86 (05)
  • [28] Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial
    Motzer, Robert J.
    Penkov, Konstantin
    Uemura, Hirotsugu
    Campbell, Matthew T.
    Kollmannsberger, Christian K.
    Lee, Jae-Lyun
    Venugopal, Balaji
    Van Den Eertwegh, Alfonsus
    Negrier, Sylvie
    Gurney, Howard
    Albiges, Laurence
    Berger, Raanan
    Haanen, John
    Rini, Brian I.
    Larkin, James
    Schmidinger, Manuela
    Sandner, Robin
    Wang, Jing
    Di Pietro, Alessandra
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
    Bilen, Mehmet A.
    Rini, Brian, I
    Voss, Martin H.
    Larkin, James
    Haanen, John B. A. G.
    Albiges, Laurence
    Pagliaro, Lance C.
    Voog, Eric G.
    Lam, Elaine T.
    Kislov, Nikolay
    McGregor, Bradley A.
    Lalani, Aly-Khan A.
    Huang, Bo
    di Pietro, Alessandra
    Krulewicz, Stan
    Robbins, Paul B.
    Choueiri, Toni K.
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 738 - 747
  • [30] Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
    Choueiri, T. K.
    Larkin, J.
    Pal, S.
    Motzer, R. J.
    Rini, B., I
    Venugopal, B.
    Alekseev, B.
    Miyake, H.
    Gravis, G.
    Bilen, M. A.
    Hariharan, S.
    Chudnovsky, A.
    Ching, K. A.
    Mu, X. J.
    Mariani, M.
    Robbins, P. B.
    Huang, B.
    di Pietro, A.
    Albiges, L.
    ESMO OPEN, 2021, 6 (03)
12345